Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR.

Clin Rheumatol 2019 Apr 17. Epub 2019 Apr 17.

Santiago University Clinical Hospital Institute of Medical Research, Santiago de Compostela, Spain.

Objective: Most reports on serious infections (SI) in rheumatoid arthritis (RA) patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) are from the USA and Western Europe. Data from other regions are largely missing. We report data from South American countries with different backgrounds and health-care systems but similar registries.

Methods: We merged 2010-2016 data from two registries, BIOBADABRASIL (Brazil) and BIOBADASAR (Argentina), which share the same protocol, online platform and data monitoring process. Patients with active RA were included when they began the first bDMARD or a conventional synthetic DMARD (csDMARD, control group). The SI incidence rate (IR) per 1000 patient/years and adjusted IR ratio (aIRR) were estimated for bDMARDs and csDMARDs.

Results: Data were analysed for 3717 RA patients with an exposure of 13,380 patient/years. The 2591 patients treated with bDMARDs (64% tumour necrosis factor-α inhibitors (TNFi)) had a follow-up of 9300 years, and the 1126 treated with csDMARDs had an exposure of 4081 patient/years. The SI IR was 30.54 (CI 27.18-34.30) for all bDMARDs and 5.15 (CI 3.36-7.89) for csDMARDs. The aIRR between the two groups was 2.03 ([1.05, 3.9] p = 0.034) for the first 6 months of treatment but subsequently increased to 8.26 ([4.32, 15.76] p < 0.001). The SI IR for bDMARDs decreased over time in both registries, dropping from 36.59 (28.41-47.12) in 2012 to 7.27 (4.79-11.05) in 2016.

Conclusion: While SI remains a major concern in South American patients with RA treated with bDMARDs, a favourable trend toward a reduction was observed in the last years. Key Points • New comprehensive data on biologic drugs safety from international collaboration in South America. • First proposal for national registries data merging in South America. • Serious infections remain a major concern in RA patients treated with biologics. • A significant reduction of serious infections in RA patients exposed to biologics was observed over a 7 years period.

Download full-text PDF

Source Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
April 2019
2 Reads

Publication Analysis

Top Keywords

serious infections
arthritis patients
patients treated
data south
registries biobadabrasil
south american
rheumatoid arthritis
adjusted ratio
ratio airr
13380 patient/years
patient/years adjusted
patient/years 2591
rate 1000
1000 patient/years
airr estimated
exposure 13380
incidence rate
data analysed


(Supplied by CrossRef)
Article in Ann Rheum Dis
S Ramiro et al.
Ann Rheum Dis 2017
Article in Ann Rheum Dis
WG Dixon et al.
Ann Rheum Dis 2010
Article in Clin Exp Rheumatol
L Carmona et al.
Clin Exp Rheumatol 2014
Article in Rev Bras Reumatol
D Titton et al.
Rev Bras Reumatol 2011
Article in Revista Argentina de Reumatologia
M Vega de la et al.
Revista Argentina de Reumatologia 2013
Article in Ann Rheum Dis
A Zink et al.
Ann Rheum Dis 2009
Article in Semin Arthritis Rheum
JR Curtis et al.
Semin Arthritis Rheum 2010
Article in Semin Arthritis Rheum
C Pease et al.
Semin Arthritis Rheum 2011
Article in Advances in Rheumatology
LMH Mota da et al.
Advances in Rheumatology 2018

Similar Publications